Your browser doesn't support javascript.
loading
Lung metastasis and lymph node metastasis are risk factors for hyperprogressive disease in primary liver cancer patients treated with immune checkpoint inhibitors.
Xiao, Lu-Shan; Li, Qi-Mei; Hu, Cheng-Yi; Cui, Hao; Hong, Chang; Huang, Chao-Yi; Li, Rui-Ning; Dong, Zhong-Yi; Zhu, Hong-Bo; Liu, Li.
Afiliación
  • Xiao LS; Big Data Center, Nanfang Hospital, Southern Medical University, Guangzhou, China; Department of Infectious Diseases, Nanfang Hospital, Southern Medical University, Guangzhou, China.
  • Li QM; Big Data Center, Nanfang Hospital, Southern Medical University, Guangzhou, China; Department of Infectious Diseases, Nanfang Hospital, Southern Medical University, Guangzhou, China.
  • Hu CY; Big Data Center, Nanfang Hospital, Southern Medical University, Guangzhou, China; Department of Infectious Diseases, Guangzhou First People's Hospital, Guangzhou, China.
  • Cui H; Department of Infectious Diseases, Nanfang Hospital, Southern Medical University, Guangzhou, China.
  • Hong C; Department of Infectious Diseases, Nanfang Hospital, Southern Medical University, Guangzhou, China.
  • Huang CY; Department of Infectious Diseases, Nanfang Hospital, Southern Medical University, Guangzhou, China.
  • Li RN; Department of Infectious Diseases, Nanfang Hospital, Southern Medical University, Guangzhou, China.
  • Dong ZY; Department of Radiation Oncology, Nanfang Hospital, Southern Medical University, Guangzhou, China.
  • Zhu HB; Department of Oncology, the First Affiliated Hospital of University of South China, Hengyang, China.
  • Liu L; Big Data Center, Nanfang Hospital, Southern Medical University, Guangzhou, China; Department of Infectious Diseases, Nanfang Hospital, Southern Medical University, Guangzhou, China.
Ann Palliat Med ; 10(11): 11244-11254, 2021 Nov.
Article en En | MEDLINE | ID: mdl-34670386
BACKGROUND: At present, some cancer patients experience hyperprogressive disease (HPD) after receiving immunotherapy. This study used the Response Evaluation Criteria in Solid Tumors 1.1 to evaluate the incidence of HPD in patients receiving immune checkpoint inhibitors (ICIs) for treating primary liver cancer (PLC) and to explore the risk factors for HPD. METHODS: This retrospective, single-center study included patients with PLC who were treated with ICIs. The RECIST 1.1 was used to determine patients with HPD. Univariate and multivariate regression analyses were performed to explore the risk factors for HPD, and clinical variables with prognostic significance for HPD were included to establish a risk model. RESULTS: Among 129 patients with PLC treated with ICIs, HPD occurred in 13 patients (10.1%). In the multivariate regression analysis, lymph node metastasis and lung metastasis were risk factors for HPD. The area under the curve of the risk model, established by including lymph node metastasis, lung metastasis, neutrophil-lymphocyte ratio, albumin, and performance status, was 0.801 (P<0.001). The progression-free survival of HPD patients was significantly worse than that of non-HPD patients (P<0.001). CONCLUSIONS: In this study, 10.1% of patients with PLC had HPD. Compared with the non-HPD patients, lung metastasis and lymph node metastasis were independent risk factors of HPD.
Asunto(s)
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Carcinoma de Pulmón de Células no Pequeñas / Neoplasias Hepáticas / Neoplasias Pulmonares Tipo de estudio: Etiology_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Límite: Humans Idioma: En Revista: Ann Palliat Med Año: 2021 Tipo del documento: Article País de afiliación: China Pais de publicación: China
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Carcinoma de Pulmón de Células no Pequeñas / Neoplasias Hepáticas / Neoplasias Pulmonares Tipo de estudio: Etiology_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Límite: Humans Idioma: En Revista: Ann Palliat Med Año: 2021 Tipo del documento: Article País de afiliación: China Pais de publicación: China